Since in vitro glucose concentrations and blood glucose levels clinically correlate with glioblastoma cell survival and tumor growth, metformin and resveratrol’s blood glucose-decreasing functions—increasing glucose uptake and insulin sensitivity—cause glucose-dependent anticancer effects of MET and RES. This evidence concerns the gene INS and neoplasm.